EA200971060A1 - Гетероариламидные пиримидоновые производные - Google Patents

Гетероариламидные пиримидоновые производные

Info

Publication number
EA200971060A1
EA200971060A1 EA200971060A EA200971060A EA200971060A1 EA 200971060 A1 EA200971060 A1 EA 200971060A1 EA 200971060 A EA200971060 A EA 200971060A EA 200971060 A EA200971060 A EA 200971060A EA 200971060 A1 EA200971060 A1 EA 200971060A1
Authority
EA
Eurasian Patent Office
Prior art keywords
group
alkyl group
groups
hydrogen atom
alkyl
Prior art date
Application number
EA200971060A
Other languages
English (en)
Inventor
Натали Шерез
Тьерри Галле
Алистер Локхед
Мурад Саади
Коринн Вероник
Филипп Иэш
Original Assignee
Санофи-Авентис
Мицубиси Танабе Фарма Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофи-Авентис, Мицубиси Танабе Фарма Корпорейшн filed Critical Санофи-Авентис
Publication of EA200971060A1 publication Critical patent/EA200971060A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Раскрыто пиримидоновое производное, представленное формулой (I), или его соль, или сольват или гидратгде Х представляет два атома водорода, атом серы, атом кислорода или Cалкильную группу и атом водорода; Z представляет связь, атом кислорода, атом азота, замещенный атомом водорода или Cалкильной группой, атом серы, метиленовую группу необязательно замещенную одной или двумя группами, выбранными из Cалкильной группы, гидроксильной группы, Cалкоксигруппы, Cпергалоидированной алкильной группы или аминогруппы; R1 представляет 2-, 4- или 5-пиримидиновое кольцо или 4-пиридиновое кольцо, причем кольцо необязательно замещено Cалкильной группой, Cалкоксигруппой или атомом галогена; R2 представляет 4-15-членную гетероциклическую группу, причем данная группа необязательно замещена 1-4 заместителями, выбранными из Cалкильной группы, атомов галогена, Cпергалоидированной алкильной группы, Cгалогенированной алкильной группы, гидроксильной группы, Cалкоксигруппы, Cпергалоидированной алкоксигруппы, Cгалогенированной алкоксигруппы, нитро, циано, амино, Cмоноалкиламиногруппы, Сдиалкиламиногруппы, S-(Cалкильной) группы, гетероциклической группы, арильной группы, гетероарильной группы, O-арильной группы или S-арильной группы, причем вышеупомянутые группы необязательно замещены 1-4 заместителями, выбранными из Cалкильной группы, атомов галогена, Cалкоксигруппы, C(O)O(C-алкильной) или С(О)О(арильной) группы, причем арил необязательно замещен 1-4 заместителями, выбранными из Cалкильной группы, атомов галогена, Cалкоксигруппы; R3 представляет атом водорода, Cалкильную группу или атомы галогена; R4 представляет атом водорода или Cалкильную группу; R5 представляет атом водорода, Cалкильную группу; R6 представляет атом водорода, Cалкильную группу; R7 представляет атом водорода или Cалкильную группу; и n равно 0-3 и m равно 0, в форме свободного основания или соли присоединения кислоты.
EA200971060A 2007-05-16 2008-05-14 Гетероариламидные пиримидоновые производные EA200971060A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07290627A EP1992621A1 (en) 2007-05-16 2007-05-16 Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases
PCT/IB2008/002429 WO2008155666A2 (en) 2007-05-16 2008-05-14 Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
EA200971060A1 true EA200971060A1 (ru) 2010-04-30

Family

ID=38261656

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200971060A EA200971060A1 (ru) 2007-05-16 2008-05-14 Гетероариламидные пиримидоновые производные

Country Status (15)

Country Link
US (1) US8598175B2 (ru)
EP (2) EP1992621A1 (ru)
JP (1) JP5508256B2 (ru)
KR (1) KR20100016510A (ru)
CN (1) CN101679306B (ru)
AR (1) AR066605A1 (ru)
AU (1) AU2008264898A1 (ru)
BR (1) BRPI0811094A2 (ru)
CA (1) CA2687255A1 (ru)
EA (1) EA200971060A1 (ru)
IL (1) IL201449A0 (ru)
MX (1) MX2009012376A (ru)
NZ (1) NZ581162A (ru)
TW (1) TW200906803A (ru)
WO (1) WO2008155666A2 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2282735B1 (en) 2008-04-21 2019-01-16 Signum Biosciences, Inc. Pp2a modulators for treating alzheimer, parkinson, diabetes
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CA2945263A1 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
US11098010B2 (en) 2017-03-21 2021-08-24 Arbutus Biopharma Corporation Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4145423A (en) * 1976-02-10 1979-03-20 Rhone-Poulenc Industries Pyrimidinyl-1,2-dithiole compounds and anti-bilharzia compositions thereof
US5629322A (en) 1994-11-15 1997-05-13 Merck & Co., Inc. Cyclic amidine analogs as inhibitors of nitric oxide synthase
JP4533534B2 (ja) 1998-06-19 2010-09-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド グリコーゲンシンターゼキナーゼ３のインヒビター
TWI241298B (en) 1998-09-25 2005-10-11 Mitsubishi Chem Corp Pyrimidone derivatives
EP1430056B1 (en) * 2001-09-21 2005-10-26 Sanofi-Aventis Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives for neurodegenerative disorders
US7683069B2 (en) 2002-12-16 2010-03-23 Mitsubishi Tanabe Pharma Corporation 3-substituted-4-pyrimidone derivatives
EP1454909B1 (en) * 2003-03-07 2008-08-20 Sanofi Aventis 8'-pyridinyl-dihydrospiro (cycloalkyl) -pyrimido (1,2-a) pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro (cycloalkyl) pyrimido (1,2-a) pyrimidin-6 derivatives -one and their use against neurodegenerative diseases
CA2516934C (en) * 2003-03-07 2011-09-20 Sanofi-Aventis Substituted 2-(diaza-bicyclo-alkyl)-pyrimidone derivatives
EP1790649A1 (en) 2005-11-21 2007-05-30 Sanofi-Aventis Substituted bicyclic pyrimidone derivatives

Also Published As

Publication number Publication date
JP5508256B2 (ja) 2014-05-28
US20100081677A1 (en) 2010-04-01
NZ581162A (en) 2011-10-28
AR066605A1 (es) 2009-09-02
EP2162443A2 (en) 2010-03-17
TW200906803A (en) 2009-02-16
EP2162443B1 (en) 2013-07-31
US8598175B2 (en) 2013-12-03
AU2008264898A1 (en) 2008-12-24
MX2009012376A (es) 2009-12-03
KR20100016510A (ko) 2010-02-12
CN101679306A (zh) 2010-03-24
EP1992621A1 (en) 2008-11-19
CA2687255A1 (en) 2008-12-24
WO2008155666A2 (en) 2008-12-24
IL201449A0 (en) 2010-05-31
JP2010526864A (ja) 2010-08-05
BRPI0811094A2 (pt) 2014-12-09
CN101679306B (zh) 2011-12-28
WO2008155666A3 (en) 2009-04-09

Similar Documents

Publication Publication Date Title
EA200971061A1 (ru) Пиримидоновые соединения гетероариламидов
EA200971060A1 (ru) Гетероариламидные пиримидоновые производные
EA201070891A1 (ru) Замещенные гетероариламидные производные диазепинопиримидона
EA200971062A1 (ru) Производные ариламидпиримидона
MEP8409A (en) Fused heterocyclic compound
MX2009006024A (es) Derivados de heteroaril piridopirimidona sustituidos.
EA201070889A1 (ru) Замещённые гетероариламидные производные оксазепинопиримидона
PE20210461A1 (es) Compuestos de azol-amida pesticidamente activos
EA201170098A1 (ru) Замещенные производные алкилпиримидин-4-она
EA200971063A1 (ru) Ариламидпиримидоновые соединения
RS52546B (en) 1H-BENZIMIDAZOL-4-CARBOXAMIDES SUBSTITUTED WITH QUATERNERN CARBON AT POSITION-2 ARE POWERFUL PARP INHIBITORS
EA201070890A1 (ru) Замещенные ариламидные производные оксазепинопиримидона
EA201170099A1 (ru) Замещенные пиримидин-4-оновые производные
CY1110232T1 (el) Παραγωγα 2-αρυλ-6-φαινυλ-ιμιδαζο[1,2-α]πυριδιν, η παρασκευη τους και η εφαρμογη τους στη θεραπευτικη αγωγη
EP1719763A4 (en) NEW PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (2)
HRP20070430T3 (en) (3-oxo-3,4-dihydro-quinoxalin-2-yl-amino)-benzamide derivatives and related compounds as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity
TW200745118A (en) Macrocylic inhibitors of hepatitis C virus
CY1108313T1 (el) Παραγωγα της κινολινης και η χρηση τους ως προσδεματων 5-ht6
EA201071113A1 (ru) ПОЛИЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 2-ГЕТЕРОАРИЛ-6-ФЕНИЛИМИДАЗО[1,2-α] ПИРИДИНОВ, ИХ ПОЛУЧЕНИЕ И ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ
JO2925B1 (en) New pyridine derivatives and pyrimidine derivatives (3)
RS54708B1 (en) ARYLETINYL DERIVATIVES
TW200942541A (en) Polysubstituted 6-heteroarylimidazo[1,2-α]pyridine derivatives, preparation thereof and therapeutic use thereof
HRP20090151T3 (en) Indozolone derivatives as 11b-hsd1 inhibitors
NO20092770L (no) Nye aminopyrimidinderivater som PLK1-inhibitorer
EA201070896A1 (ru) ЗАМЕЩЕННЫЕ АРИЛАМИДДИАЗЕПИНОПИРИМИДОНОВЫЕ ПРОИЗВОДНЫЕ ДЛЯ ЛЕЧЕНИЯ НЕЙРОДЕГЕНЕРАТИВНЫХ ЗАБОЛЕВАНИЙ, ВЫЗВАННЫХ АНОМАЛЬНОЙ АКТИВНОСТЬЮ GSK3β